Farhatullah Syed, Group Leader/Senior Scientist at King Faisal Specialist Hospital and Research Centre, shared on LinkedIn:
“Could CAR T cells fight solid tumors better by taking scheduled breaks?
Chen and colleagues’ outstanding study in Cell Reports Medicine introduces MANAGE CAR T cells, combining tumour targeting with externally controlled timing of CAR expression.
An albumin adapter carrying FITC, a fluorescent tag, preferentially accumulates in tumours.
A synthetic Notch receptor detects cell-bound FITC and triggers expression of a separate tumour-targeting CAR.
Spacing adapter doses creates pulses of CAR expression, with intervals of reduced stimulation.
In mice, six-day dosing intervals outperformed shorter and longer schedules tested, preserved stem-like features and reduced exhaustion markers.
Combined with PD-L1 blockade, treatment achieved complete regressions in breast cancer and glioblastoma models.
These findings suggest that externally controlling when CARs are expressed could improve solid-tumour treatment, while introducing a combined cell-and-adapter strategy whose dosing, safety and manufacturing requirements need validation before clinical translation.
These promising preclinical findings provide a strong foundation for further development.
Future studies can clarify human safety, optimal dosing intervals, manufacturing feasibility and how reduced exhaustion contributes to improved tumour control.”
Title: Temporal control of CAR expression by a tumor-targeting albumin adapter and logic gating enhances CAR-T cell therapy for solid tumors
Authors: Jin Chen, Lei Zhao, Cui Shen, Yang Zhou, Yangjing Li, Yuzheng Zhu, Mengqian Gao, Xinyue Wang, Yulun Huang, Yiran Zheng
You can also read:
Aleix Prat: A Major Step Toward Bringing CAR-T Therapies to Solid Tumors.
Miguel Bronchud: Exploring CAR-T Therapy for Colorectal and Other Solid Tumors.